IC-MPGN clinical trials at UCSF
1 research study open to eligible people
IC-MPGN is a kidney disease that causes inflammation and damage to the kidney filters. UCSF is conducting a study to test the safety and effectiveness of a drug called Iptacopan for people with IC-MPGN. This trial includes different groups and compares the drug to a placebo.
Showing trials for
Iptacopan in Participants With IC-MPGN
open to eligible people ages 12-60
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
San Francisco, California and other locations
Our lead scientists for IC-MPGN research studies include Raymond Hsu.
Last updated: